Table 3.
Risk of death of any cause or of breast cancer for adolescents and young adults (15 to 39 years of age) with breast cancer by tumor grade*, California, 2005-2009
|
All-cause deaths |
Breast cancer-specific deaths |
|||
|---|---|---|---|---|
| Number of deaths | HR (95% CI)* | Number of deaths | HR (95% CI)* | |
| Low tumor grade (I/II) |
|
|
|
|
| Subtype† |
|
|
|
|
| HR+/HER2- |
44 |
1.00 (reference) |
27 |
1.00 (reference) |
| HR+/HER2+ |
19 |
1.57 (0.87-2.81) |
16 |
2.23 (1.12-4.44) |
| HR-/HER2+ |
9 |
1.52 (0.61-3.76) |
7 |
2.37 (0.85-6.61) |
| Triple negative |
25 |
10.64 (5.66-20.00) |
21 |
13.87 (6.49-29.64) |
| Unclassified |
16 |
1.34 (0.70-2.57) |
13 |
2.05 (0.95-4.44) |
| High tumor grade (III) |
|
|
|
|
| Subtype† |
|
|
|
|
| HR+/HER2- |
73 |
1.00 (reference) |
67 |
1.00 (reference) |
| HR+/HER2+ |
23 |
0.49 (0.29-0.81) |
21 |
0.48 (0.28-0.81) |
| HR-/HER2+ |
59 |
1.40 (0.95-2.06) |
55 |
1.40 (0.93-2.10) |
| Triple negative |
162 |
2.24 (1.61-3.13) |
140 |
2.14 (1.51-3.04) |
| Unclassified | 57 | 1.47 (0.98-2.21) | 49 | 1.32 (0.85-2.05) |
* Cox models were adjusted for all variables presented in Table 2 and age at diagnosis (continuous), tumor size (continuous), and first course of treatment (chemotherapy (y/n), radiation (y/n), and surgery (y/n)); AJCC stage levels I-IV and unknown was included as a stratifying variable. P for interaction between breast cancer subtype and grade = 0.018 for all-cause mortality and =0.0735 for breast cancer-specific mortality.
† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).